|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Highland Instruments, Inc. , Announces Institutional Review Board ("IRB") Approval to Initiate Clinical Evaluation of Non-Invasive Brain Stimulation Technologies In Patients With Parkinson's Disease
10/23/2012 9:05:46 AM
BOSTON--(BUSINESS WIRE)--Highland Instruments, Inc., (“Highland”) today announced IRB approval to initiate a clinical evaluation of Highland’s ElectroSonic Stimulation (“ESStim™”) technology for the treatment of Parkinson’s Disease (“PD”)1. The clinical evaluation “Effects of Non-Invasive Neurostimulation Methods on Motor Function in Parkinson’s Disease Patients” will be conducted at the Spaulding Rehabilitation (“Spaulding”) Hospital’s Laboratory of Neuromodulation (Boston). Felipe Fregni, MD, PhD, MPH, will be the Lead Clinical Investigator. Dr. Fregni is the Director of the Laboratory of Neuromodulation at Spaulding Rehabilitation Hospital and Associate Professor of Neurology at Harvard Medical School. Bill Edelman, Chairman of the Board for Highland, commented, “We are thrilled to have received IRB approval to initiate the clinical evaluation of ESStim in patients with Parkinson’s Disease. Dr. Fregni is a pioneer in the world of non-invasive brain stimulation, having conducted groundbreaking trials exploring neuromodulation treatments for chronic pain, Parkinson's disease, and stroke.”
|
|
|
|
|
|
|
|
|
|
|